Enhancement by vaso‐active intestinal peptide of gastric carcinogenesis induced by N‐methyl‐N'‐nitro‐N‐nitrosoguanidine in rats

The effects of vaso‐active intestinal peptide (VIP) on gastric carcinogenesis induced by N‐methyl‐N'‐nitro‐N‐nitrosoguanidine (MNNG) were investigated in Wistar rats given VIP every other day for 27 weeks after oral administration of MNNG for 25 weeks. In week 52, administration of VIP caused a significant increase in the incidence of gastric cancers, but did not influence their histological appearance. VIP significantly increased the labeling indices of the antral mucosa. Our findings indicate that VIP enhances gastric carcinogenesis, and that this effect may be related to its effect in increasing cell proliferation of the antral epithelial cells.

[1]  E. Scholar,et al.  Stimulation of tumor cell growth by vasoactive intestinal peptide , 1991, Cancer.

[2]  H. Iishi,et al.  Effect of cimetidine on inhibition by tetragastrin of carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. , 1988, Cancer research.

[3]  H. Iishi,et al.  Inhibitory effect of prolonged administration of cysteamine on experimental carcinogenesis in rat stomach induced by N‐methyl‐N′‐nitro‐N‐nitrosoguanidine , 1988, International journal of cancer.

[4]  H. Iishi,et al.  Enhancement by vasoactive intestinal peptide of experimental carcinogenesis induced by azoxymethane in rat colon. , 1987, Cancer research.

[5]  S. Poulsen,et al.  Effect of vasoactive intestinal polypeptide and somatostatin on secretion of epidermal growth factor and bicarbonate from Brunner's glands. , 1984, Gut.

[6]  S. Said.  Vasoactive intestinal polypeptide (VIP): Current status , 1984, Peptides.

[7]  T. Kinsella,et al.  Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody. , 1983, The Journal of clinical investigation.

[8]  C. Gespach,et al.  Histamine and VIP interactions with receptor-cyclic AMP systems in the human gastric cancer cell line HGT-1. , 1983, Life sciences.

[9]  C. Gespach,et al.  Regulation by vasoactive intestinal peptide, histamine, somatostatin-14 and -28 of cyclic adenosine monophosphate levels in gastric glands isolated from the guinea pig fundus or antrum. , 1983, Endocrinology.

[10]  H. Gratzner,et al.  Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. , 1982, Science.

[11]  O. Kobori,et al.  Growth responses of rat stomach cancer cells to gastro‐entero‐pancreatic hormones , 1982, International journal of cancer.

[12]  H. Masui,et al.  Hormonal control of human colon carcinoma cell growth in serum-free medium. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Smith,et al.  Monosaccharide transport across microvillous membrane of human placenta. , 1980, The American journal of physiology.

[14]  M. Laburthe,et al.  Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 2. Characterization and structural requirements of the stimulatory effect of vasoactive intestinal peptide on production of adenosine 3':5'-monophosphate. , 1979, European journal of biochemistry.

[15]  M. Laburthe,et al.  Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 1. Characterization, quantitative aspects and structural requirements of binding sites. , 1979, European journal of biochemistry.

[16]  M. Rousset,et al.  Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Tatsuta,et al.  Effect of prolonged administration of gastrin on experimental carcinogenesis in rat stomach induced by N-methyl-N' -nitro-N-nitrosoguanidine. , 1977, Cancer research.

[18]  L. Johnson,et al.  New aspects of the trophic action of gastrointestinal hormones. , 1977, Gastroenterology.

[19]  J. Polak,et al.  The newer gut hormones. Cellular sources, physiology, pathology, and clinical aspects. , 1977, Gastroenterology.

[20]  D. Friedman.  Role of cyclic nucleotides in cell growth and differentiation. , 1976, Physiological reviews.

[21]  P. Robberecht,et al.  Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. , 1976, The Journal of biological chemistry.

[22]  D. Bataille,et al.  Interactions of glucagon, gut glucagon, vasoactive intestinal polypeptide and secretin with liver and fat cell plasma membranes: binding to specific sites and stimulation of adenylate cyclase. , 1974, Endocrinology.

[23]  B. Desbuquois.  The interaction of vasoactive intestinal polypeptide and secretin with liver-cell membranes. , 1974, European journal of biochemistry.

[24]  M. Stefanini,et al.  Fixation of Ejaculated Spermatozoa for Electron Microscopy , 1967, Nature.

[25]  S. Siegel,et al.  Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.

[26]  H. Shay,et al.  A quantitative method for measuring spontaneous gastric secretion in the rat. , 1954, Gastroenterology.

[27]  J. Silverlight,et al.  Oestradiol, vasoactive intestinal peptide and fibroblast growth factor in the growth of human pituitary tumour cells in vitro. , 1989, The Journal of endocrinology.

[28]  M. Tatsuta,et al.  Effect of fundusectomy on serum and antral gastrin levels in rats. , 1977, Gastroenterology.

[29]  G. S. Johnson,et al.  Role of cyclic nucleotides in growth control. , 1975, Annual review of biochemistry.